Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, JW Pharmaceutical's Enterprise Value is ₩658,097 Mil.
JW Pharmaceutical's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was ₩104,830 Mil. Therefore, JW Pharmaceutical's EV-to-EBIT ratio for today is 6.28.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, JW Pharmaceutical's Enterprise Value is ₩658,097 Mil.
JW Pharmaceutical's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was ₩123,922 Mil. Therefore, JW Pharmaceutical's EV-to-EBITDA ratio for today is 5.31.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, JW Pharmaceutical's Enterprise Value is ₩658,097 Mil.
JW Pharmaceutical's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 was ₩789,947 Mil. Therefore, JW Pharmaceutical's EV-to-Revenue ratio for today is 0.83.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
JW Pharmaceutical (XKRX:001060) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
JW Pharmaceutical's current Enterprise Value is ₩658,097 Mil.
JW Pharmaceutical's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩104,830 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
JW Pharmaceutical's current Enterprise Value is ₩658,097 Mil.
JW Pharmaceutical's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩123,922 Mil.
JW Pharmaceutical's current Enterprise Value is ₩658,097 Mil.
JW Pharmaceutical's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩789,947 Mil.
JW Pharmaceutical's current Enterprise Value is ₩658,097 Mil.
JW Pharmaceutical's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩85,316 Mil.
JW Pharmaceutical's current Enterprise Value is ₩658,097 Mil.
JW Pharmaceutical's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩50,886 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
JW Pharmaceutical Enterprise Value Related Terms
JW Pharmaceutical Enterprise Value Historical Data
* Premium members only.
The historical data trend for JW Pharmaceutical's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, JW Pharmaceutical's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
JW Pharmaceutical Enterprise Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, JW Pharmaceutical's Enterprise Value distribution charts can be found below:
* The bar in red indicates where JW Pharmaceutical's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
JW Pharmaceutical's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Enterprise Value of ₩658,097 Mil mean?
JW Pharmaceutical (XKRX:001060) has a Enterprise Value of ₩658,097 Mil as of Aug. 18, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on JW Pharmaceutical and its competitors.
Is JW Pharmaceutical's Enterprise Value too high?
JW Pharmaceutical's current Enterprise Value is ₩658,097 Mil. Overall, JW Pharmaceutical has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does JW Pharmaceutical's Enterprise Value compare to ZTS?
JW Pharmaceutical's Enterprise Value of ₩658,097 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Drug Manufacturers company?
A good Enterprise Value depends on the Drug Manufacturers industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on JW Pharmaceutical and its competitors. JW Pharmaceutical's current Enterprise Value is ₩658,097 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is JW Pharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, JW Pharmaceutical (XKRX:001060) is currently considered Modestly Undervalued. The stock's GF Value™ is ₩32,148.31, compared to a current price of ₩28,850.00 — trading 10.3% below its estimated fair value. The current Enterprise Value is ₩658,097 Mil. JW Pharmaceutical's overall GF Score™ is 90/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For JW Pharmaceutical (XKRX:001060), the current Enterprise Value is ₩658,097 Mil as of Aug. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is JW Pharmaceutical (XKRX:001060) Overvalued in 2026?
Based on GuruFocus' analysis, JW Pharmaceutical stock appears to be undervalued.
The current stock price of ₩28,850.00 is trading 10.3% below its estimated GF Value™ of ₩32,148.31.
GuruFocus considers JW Pharmaceutical to be Modestly Undervalued.
Key valuation signals for XKRX:001060:
Enterprise Value: ₩658,097 Mil
GF Value™: ₩32,148.31 vs. price of ₩28,850.00 (10.3% below fair value)
No single metric tells the full story. See the XKRX:001060 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
JW Pharmaceutical is active in the healthcare sector. It has been one of the leading companies in the pharmaceutical market on a global basis. Its original medicine and medical supply pipeline include Livalo, Thrupas, Sigmart and Actemra. It also develops low-protein and low-salt diet food for patients suffering from chronic renal insufficiency as well as general Pharmaceuticals and health care products.
90GF Score
Get the complete analysis for XKRX:001060
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKRX:001060 has been successfully added to your 
